What do systematic reviews say?

Phacoemulsification vs laser peripheral iridotomy

• Lens extraction versus laser peripheral iridotomy for acute primary angle closure 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Phacoemulsification vs laser peripheral iridotomy

• Lens extraction versus laser peripheral iridotomy for acute primary angle closure 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Low

Phacoemulsification vs laser peripheral iridotomy

• Lens extraction versus laser peripheral iridotomy for acute primary angle closure 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 94 participants
  Very low

Phacoemulsification vs laser peripheral iridotomy

• Lens extraction versus laser peripheral iridotomy for acute primary angle closure 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 99 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in nicotine tapering (low certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.14 [1, 1.29]
  111 studies · 33156 participants
  Low

Intervention not reported

The intervention leads to higher varenicline (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 2.33 [2.02, 2.68]
  67 studies · 16430 participants
  High

Intervention not reported

The intervention leads to higher cytisine (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 2.21 [1.66, 2.97]
  7 studies · 3848 participants
  High

Intervention not reported

The intervention leads to higher nicotine patch (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.37 [1.2, 1.56]
  105 studies · 37319 participants
  High

Intervention not reported

The intervention leads to higher fast‐acting NRT (nicotine other) (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.41 [1.29, 1.55]
  120 studies · 31756 participants
  High

Intervention not reported

The intervention leads to higher nicotine EC (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 2.37 [1.73, 3.24]
  16 studies · 3828 participants
  High

Intervention not reported

The intervention showed no clear difference in non‐nicotine/placebo EC (low certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.16 [0.74, 1.8]
  8 studies · 1094 participants
  Low

Intervention not reported

The intervention leads to higher bupropion (high certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.43 [1.26, 1.62]
  71 studies · 14759 participants
  High

Intervention not reported

The intervention probably leads to higher nortriptyline (moderate certainty).

• Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses 2023 · Cochrane Headline outcomes only
  OR 1.35 [1.02, 1.81]
  10 studies · 1290 participants
  Moderate

Chlorhexidine gel (0.2%, intrasocket) vs placebo or no treatment

• Local interventions for the management of alveolar osteitis (dry socket) 2022 · Cochrane All outcomes

  Follow-up: median 7 days
  No adverse events were reported. Six trials (673 participants) reported no adverse events from the use of chlorhexidine gel; one study (Rubio-Palau 2015) reported gastrointestinal discomfort (30, 18%), dizziness (10,…
  7 studies
  GRADE not reported

Chlorhexidine gel (0.2%, intrasocket) vs Chlorhexidine mouthrinse

• Local interventions for the management of alveolar osteitis (dry socket) 2022 · Cochrane All outcomes

  Follow-up: median 7 days
  No adverse events were reported in these two trials (Abu-Mostafa 2015; Hita-Iglesias 2008).
  2 studies
  GRADE not reported

Aspirin vs placebo

Aspirin showed no clear difference in total mortality compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.97 [0.87, 1.08]
  3 studies · 35794 participants
  Low

Aspirin vs placebo

Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.98 [0.82, 1.17]
  3 studies · 35794 participants
  Low

Aspirin vs placebo

Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 0.63 [0.45, 0.87]
  1 study · 2540 participants
  Low

Aspirin vs placebo

Aspirin leads to higher major bleedinga compared with placebo (high certainty).

• Antiplatelet agents and anticoagulants for hypertension 2022 · Cochrane Headline outcomes only
  OR 1.77 [1.34, 2.32]
  2 studies · 21330 participants
  High